Molecular targeted therapy for anticancer treatment
HY Min, HY Lee - Experimental & molecular medicine, 2022 - nature.com
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
certain types of cancer, molecular targeted therapy utilizing small molecule agents or …
Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis
Simple Summary Vimentin is an important filamentous protein providing structural and
functional support to the cell. During initial stages of cancer development, vimentin …
functional support to the cell. During initial stages of cancer development, vimentin …
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies
ZD Shi, K Pang, ZX Wu, Y Dong, L Hao… - … and Targeted Therapy, 2023 - nature.com
Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …
The role of EREG/EGFR pathway in tumor progression
WL Cheng, PH Feng, KY Lee, KY Chen… - International journal of …, 2021 - mdpi.com
Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …
The 2022 report on the human proteome from the HUPO human proteome project
The 2022 Metrics of the Human Proteome from the HUPO Human Proteome Project (HPP)
show that protein expression has now been credibly detected (neXtProt PE1 level) for 18 …
show that protein expression has now been credibly detected (neXtProt PE1 level) for 18 …
Drug-tolerant persister cells in cancer therapy resistance
PK Dhanyamraju, TD Schell, S Amin, GP Robertson - Cancer research, 2022 - AACR
One of the current stumbling blocks in our fight against cancer is the development of
acquired resistance to therapy, which is attributable to approximately 90% of cancer-related …
acquired resistance to therapy, which is attributable to approximately 90% of cancer-related …
Dissecting tumor growth: the role of cancer stem cells in drug resistance and recurrence
B Aramini, V Masciale, G Grisendi, F Bertolini, M Maur… - Cancers, 2022 - mdpi.com
Simple Summary Cancer is one of the most debated problems all over the world. Cancer
stem cells are considered responsible of tumor initiation, metastasis, drug resistance, and …
stem cells are considered responsible of tumor initiation, metastasis, drug resistance, and …
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer
Cancer often develops multidrug resistance (MDR) when cancer cells become resistant to
numerous structurally and functionally different chemotherapeutic agents. MDR is …
numerous structurally and functionally different chemotherapeutic agents. MDR is …
Impact of the tumor microenvironment on tumor heterogeneity and consequences for cancer cell plasticity and stemness
R Hass, J von der Ohe, H Ungefroren - Cancers, 2020 - mdpi.com
Simple Summary The cancer cells in solid tumors are embedded in a complex connective
tissue matrix composed of various other cell types, ie, mesenchymal stroma/stem-like cells …
tissue matrix composed of various other cell types, ie, mesenchymal stroma/stem-like cells …
Iron-sensitive prodrugs that trigger active ferroptosis in drug-tolerant pancreatic cancer cells
Persister cancer cells represent rare populations of cells resistant to therapy. Cancer cells
can exploit epithelial-mesenchymal plasticity to adopt a drug-tolerant state that does not …
can exploit epithelial-mesenchymal plasticity to adopt a drug-tolerant state that does not …